ATE511510T1 - Kondensierte azol-pyrimidin-derivate - Google Patents

Kondensierte azol-pyrimidin-derivate

Info

Publication number
ATE511510T1
ATE511510T1 AT08075839T AT08075839T ATE511510T1 AT E511510 T1 ATE511510 T1 AT E511510T1 AT 08075839 T AT08075839 T AT 08075839T AT 08075839 T AT08075839 T AT 08075839T AT E511510 T1 ATE511510 T1 AT E511510T1
Authority
AT
Austria
Prior art keywords
pyrimidine derivatives
condensed azole
azole
condensed
pyrimidine
Prior art date
Application number
AT08075839T
Other languages
English (en)
Inventor
Toshiki Murata
Megumi Yamauchi
Tetsuo Kikuchi
Takashi Yoshino
Naoki Omori
Mami Miura
Hideki Tsujishita
Makoto Shimazaki
Klaus Urbahns
Kinji Fuchikami
Satoko Matsukawa
Florian Gantner
Kevin Bacon
Original Assignee
Bayer Schering Pharma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Schering Pharma Ag filed Critical Bayer Schering Pharma Ag
Application granted granted Critical
Publication of ATE511510T1 publication Critical patent/ATE511510T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Vascular Medicine (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
AT08075839T 2002-09-30 2003-09-18 Kondensierte azol-pyrimidin-derivate ATE511510T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP02021861 2002-09-30

Publications (1)

Publication Number Publication Date
ATE511510T1 true ATE511510T1 (de) 2011-06-15

Family

ID=32039115

Family Applications (2)

Application Number Title Priority Date Filing Date
AT03788908T ATE411996T1 (de) 2002-09-30 2003-09-18 Kondensierte azolpyrimidinderivate
AT08075839T ATE511510T1 (de) 2002-09-30 2003-09-18 Kondensierte azol-pyrimidin-derivate

Family Applications Before (1)

Application Number Title Priority Date Filing Date
AT03788908T ATE411996T1 (de) 2002-09-30 2003-09-18 Kondensierte azolpyrimidinderivate

Country Status (33)

Country Link
US (2) US7511041B2 (de)
EP (2) EP1549652B1 (de)
JP (1) JP4790266B2 (de)
KR (1) KR101059652B1 (de)
CN (1) CN100384846C (de)
AR (2) AR041426A1 (de)
AT (2) ATE411996T1 (de)
AU (1) AU2003293310B2 (de)
BR (1) BRPI0314830B8 (de)
CA (1) CA2499134C (de)
CY (2) CY1109790T1 (de)
DE (1) DE60324296D1 (de)
DK (2) DK1549652T3 (de)
EC (2) ECSP055768A (de)
ES (2) ES2367141T3 (de)
HK (1) HK1084393A1 (de)
HR (2) HRP20050375B1 (de)
IL (1) IL166855A (de)
MA (1) MA27483A1 (de)
MX (1) MXPA05001808A (de)
MY (1) MY140756A (de)
NO (1) NO331457B1 (de)
NZ (1) NZ539062A (de)
PE (1) PE20050089A1 (de)
PL (1) PL226562B1 (de)
PT (2) PT1549652E (de)
RU (1) RU2326881C9 (de)
SI (2) SI1549652T1 (de)
TW (1) TWI327570B (de)
UA (1) UA82205C2 (de)
UY (1) UY28001A1 (de)
WO (1) WO2004029055A1 (de)
ZA (1) ZA200503306B (de)

Families Citing this family (83)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6667300B2 (en) 2000-04-25 2003-12-23 Icos Corporation Inhibitors of human phosphatidylinositol 3-kinase delta
CA2537124C (en) 2003-08-29 2012-08-07 Mitsui Chemicals, Inc. Agricultural/horticultural insecticide and method for using the same
US7932260B2 (en) 2004-05-13 2011-04-26 Icos Corporation Quinazolinones as inhibitors of human phosphatidylinositol 3-kinase delta
CA2579279C (en) 2004-10-07 2013-10-01 Boehringer Ingelheim International Gmbh Tricyclic thiazole derivatives as pi3 kinases
WO2006040645A1 (en) * 2004-10-11 2006-04-20 Ranbaxy Laboratories Limited N-(3,5-dichloropyridin-4-yl)-2,4,5-alkoxy and 2,3,4-alkoxy benzamide derivatives as pde-iv (phophodiesterase type-iv) inhibitors for the treatment of inflammatory diseases such as asthma
EP3770278A1 (de) 2005-04-14 2021-01-27 The Trustees of Boston University Diagnose für lungenerkrankungen mittels klassenvorhersage
UA97348C2 (en) * 2005-07-29 2012-02-10 4Сц Аг HETEROCYCLIC NF-kB INHIBITORS
CA2645310A1 (en) 2006-03-09 2007-09-13 The Trustees Of Boston University Diagnostic and prognostic methods for lung disorders using gene expression profiles from nose epithelial cells
US7691868B2 (en) 2006-04-06 2010-04-06 Boehringer Ingelheim International Gmbh Thiazolyl-dihydro-quinazoline
US7517995B2 (en) * 2006-04-06 2009-04-14 Boehringer Ingelheim International Gmbh Thiazolyl-dihydro-cyclopentapyrazole
ATE532788T1 (de) * 2006-04-26 2011-11-15 Hoffmann La Roche Pharmazeutische verbindungen
WO2008064244A2 (en) * 2006-11-20 2008-05-29 The Trustees Of Columbia University In The City Of New York Phosphoinositide modulation for the treatment of neurodegenerative diseases
AR064106A1 (es) * 2006-12-05 2009-03-11 Bayer Schering Pharma Ag Derivados de 2,3-dihidroimidazo [1,2-c] quinazolina sustituida utiles para el tratamiento de enfermedades y trastornos hiper-proliferativos asociados con la angiogenesis
EP1953163A1 (de) * 2007-02-01 2008-08-06 Boehringer Ingelheim Pharma GmbH & Co. KG Pteridinon-Derivate als PI3-Kinases Inhibitoren
WO2008148023A2 (en) * 2007-05-23 2008-12-04 Medical College Of Georgia Research Institute, Inc. Compositions and methods for treating neurological disorders
WO2009039140A1 (en) * 2007-09-17 2009-03-26 Smithkline Beecham Corporation Pyridopyrimidine derivatives as pi3 kinase inhibitors
EP2193211A4 (de) * 2007-09-19 2010-12-08 Univ Boston Identfizierung neuer wege zur wirkstoffentwicklung für lungenleiden
JP5620275B2 (ja) * 2008-01-14 2014-11-05 バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングＢａｙｅｒ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ ＧｍｂＨ 超増殖性疾患及び脈管形成に関連する疾病を処理するために有用なスルホン置換された２，３−ジヒドロイミダゾ［１，２−ｃ］キナゾリン誘導体類
JP5581219B2 (ja) 2008-01-25 2014-08-27 ミレニアム ファーマシューティカルズ， インコーポレイテッド チオフェンおよびホスファチジルイノシトール３−キナーゼ（ｐｉ３ｋ）阻害薬としてのその使用
WO2009111547A1 (en) * 2008-03-04 2009-09-11 Wyeth 7h-pyrrolo[2,3-h]quinazoline compounds, their use as mtor kinase and pi3 kinase inhibitors, and their synthesis
WO2009128520A1 (ja) * 2008-04-18 2009-10-22 塩野義製薬株式会社 Ｐ１３ｋ阻害活性を有する複素環化合物
EP2303890A4 (de) * 2008-06-19 2012-04-11 Progenics Pharm Inc Inhibitoren von phosphatidylinosit-3-kinase
EP2168582A1 (de) 2008-09-24 2010-03-31 Bayer Schering Pharma Aktiengesellschaft Kombinationen aus substituierten 2,3-dihydroimidazo[1,2-c]chinazolinen
EP2168583A1 (de) 2008-09-24 2010-03-31 Bayer Schering Pharma Aktiengesellschaft Verwendungen von substituierten 2,3-Dihydroimidazo[1,2-c]quinazolinen zur Behandlung von Myelom
ES2614130T3 (es) * 2008-09-30 2017-05-29 Pfizer Inc. Compuestos de imidazo[1,5]naftiridina, su uso farmacéutico y composiciones
BRPI0915273B1 (pt) * 2008-11-11 2021-08-03 Je Il Pharmaceutical Co., Ltd Derivado tricíclico ou seus sais farmaceuticamente aceitáveis e seus métodos de preparação
US9492449B2 (en) 2008-11-13 2016-11-15 Gilead Calistoga Llc Therapies for hematologic malignancies
ES2674719T3 (es) 2008-11-13 2018-07-03 Gilead Calistoga Llc Terapias para neoplasias hematológicas
US9495515B1 (en) 2009-12-09 2016-11-15 Veracyte, Inc. Algorithms for disease diagnostics
CA2750935A1 (en) 2009-01-30 2010-08-12 Millennium Pharmaceuticals, Inc. Heteroaryls and their use as pi3k inhibitors
US9090601B2 (en) 2009-01-30 2015-07-28 Millennium Pharmaceuticals, Inc. Thiazole derivatives
EP2411391A1 (de) 2009-03-24 2012-02-01 Gilead Calistoga LLC Atropisomere von 2-purinyl-3-tolylchinazolinonderivaten und anwendungsverfahren
CN102458410A (zh) 2009-04-20 2012-05-16 吉联亚·卡利斯托加有限责任公司 治疗实体瘤的方法
SI2899191T1 (sl) * 2009-04-30 2017-11-30 Glaxo Group Limited Z oksazolom substituirani indazoli kot PI3-kinazni inhibitorji
CN102647987A (zh) 2009-07-21 2012-08-22 吉里德卡利斯托加公司 使用pi3k抑制剂治疗肝脏障碍
NZ626650A (en) * 2009-09-09 2015-12-24 Celgene Avilomics Res Inc Pi3 kinase inhibitors and uses thereof
MX2012012064A (es) * 2010-04-16 2012-12-17 Bayer Ip Gmbh Combinaciones que contienen 2,3-dihidroimidazo[1,2-c]quinazolina sustituida.
WO2012021611A1 (en) 2010-08-11 2012-02-16 Millennium Pharmaceuticals, Inc. Heteroaryls and uses thereof
US9381177B2 (en) 2010-10-01 2016-07-05 Bayer Intellectual Property Gmbh Substituted N-(2-arylamino)aryl sulfonamide-containing combinations
CN103370320B (zh) * 2010-11-11 2016-04-27 拜耳知识产权有限责任公司 芳基氨基醇取代的2,3-二氢咪唑并[1,2-c]喹啉
ES2646012T3 (es) 2010-11-11 2017-12-11 Bayer Intellectual Property Gmbh 2,3-Dihidroimidazo[1,2-c]quinazolinas sustituidas con alcoxi
UA113280C2 (xx) * 2010-11-11 2017-01-10 АМІНОСПИРТЗАМІЩЕНІ ПОХІДНІ 2,3-ДИГІДРОІМІДАЗО$1,2-c]ХІНАЗОЛІНУ, ПРИДАТНІ ДЛЯ ЛІКУВАННЯ ГІПЕРПРОЛІФЕРАТИВНИХ ПОРУШЕНЬ І ЗАХВОРЮВАНЬ, ПОВ'ЯЗАНИХ З АНГІОГЕНЕЗОМ
JO3733B1 (ar) 2011-04-05 2021-01-31 Bayer Ip Gmbh استخدام 3,2-دايهيدروايميدازو[1, 2 -c]كوينازولينات مستبدلة
EP2508525A1 (de) 2011-04-05 2012-10-10 Bayer Pharma Aktiengesellschaft Substituierte 2,3-Dihydroimidazo[1,2-c]chinazolinsalze
AR090253A1 (es) 2012-03-05 2014-10-29 Gilead Calistoga Llc Formas polimorficas de (s)-2-(1-(9h-purin-6-ilamino)propil)-5-fluor-3-fenilquinazolin-4(3h)-ona
EP2968988A4 (de) 2013-03-14 2016-11-16 Allegro Diagnostics Corp Verfahren zur bewertung eines copd-status
US20160143910A1 (en) 2013-03-15 2016-05-26 Constellation Pharmaceuticals, Inc. Methods of treating cancer and preventing cancer drug resistance
US11976329B2 (en) 2013-03-15 2024-05-07 Veracyte, Inc. Methods and systems for detecting usual interstitial pneumonia
PE20151780A1 (es) 2013-04-08 2015-12-20 Bayer Pharma AG Uso de 2 - 3 dihidroimidazo[ 1,2- c] quinazolinas sustituidas
WO2014177060A1 (en) 2013-05-01 2014-11-06 F.Hoffmann-La Roche Ag Biheteroaryl compounds and uses thereof
WO2015027431A1 (en) * 2013-08-29 2015-03-05 Merck Sharp & Dohme Corp. 2,2-difluorodioxolo a2a receptor antagonists
US9708327B2 (en) 2013-12-20 2017-07-18 Gilead Calistoga Llc Polymorphic forms of a hydrochloride salt of (S)-2-(1-(9H-purin-6-ylamino)propyl)-5-fluoro-3-phenylquinazolin-4(3H)-one
MX2016008259A (es) 2013-12-20 2016-10-13 Gilead Calistoga Llc Metodo de proceso para inhibidores de fosfatidilinositol 3-cinasa.
SG11201609877XA (en) 2014-06-13 2016-12-29 Gilead Sciences Inc Phosphatidylinositol 3-kinase inhibitors
EP3770274A1 (de) 2014-11-05 2021-01-27 Veracyte, Inc. Systeme und verfahren zur diagnose von idiopathischer pulmonaler fibrose auf transbronchialen biopsien mit maschinellem lernen und hochdimensionalen transkriptionsdaten
EP3018127A1 (de) 2014-11-07 2016-05-11 Bayer Pharma Aktiengesellschaft Synthese von Copanlisib sowie dessen Dihydrochloridsalz
EP3018131A1 (de) 2014-11-07 2016-05-11 Bayer Pharma Aktiengesellschaft Synthese von Copanlisib sowie dessen Dihydrochloridsalz
SG11201707240SA (en) 2015-03-09 2017-10-30 Bayer Pharma AG Substituted 2,3-dihydroimidazo[1,2-c]quinazoline-containing combinations
CN105130997B (zh) * 2015-09-25 2017-12-05 苏州明锐医药科技有限公司 一种库潘尼西的制备方法
CN105130998B (zh) * 2015-09-25 2017-07-28 苏州立新制药有限公司 库潘尼西的制备方法
WO2017153220A1 (en) 2016-03-08 2017-09-14 Bayer Pharma Aktiengesellschaft 2—amino—n— [7—methoxy—2, 3-dihydroimidazo-[1, 2-c] quinazolin-5-yl] pyrimidine—5—carboxamides
EP3219329A1 (de) 2016-03-17 2017-09-20 Bayer Pharma Aktiengesellschaft Kombinationen von copanlisib
US10927417B2 (en) 2016-07-08 2021-02-23 Trustees Of Boston University Gene expression-based biomarker for the detection and monitoring of bronchial premalignant lesions
JP2019532922A (ja) 2016-09-23 2019-11-14 バイエル ファーマ アクチエンゲゼルシャフト Ｐｉ３ｋ−阻害剤の組み合わせ
WO2018112176A1 (en) 2016-12-14 2018-06-21 Tarveda Therapeutics, Inc. Hsp90-targeting conjugates and formulations thereof
EP3585437B1 (de) 2017-02-24 2022-12-21 Bayer Pharma Aktiengesellschaft Kombinationen von copanlisib mit anti-pd-1-antikörper
CA3068324A1 (en) 2017-06-28 2019-01-03 Bayer Consumer Care Ag Combination of a pi3k-inhibitor with an androgen receptor antagonist
HUE063178T2 (hu) 2017-09-08 2023-12-28 Bayer Pharma AG Kopanlizib formulációi
EP3498266A1 (de) 2017-12-15 2019-06-19 Bayer Consumer Care AG Formulierungen von copanlisib
JP7394768B2 (ja) * 2017-09-20 2023-12-08 エイビーエム セラピューティックス コーポレイション キナーゼ阻害剤としての環状イミノピリミジン誘導体
US11351156B2 (en) 2017-10-13 2022-06-07 Inserm Combination treatment of pancreatic cancer
WO2019101871A1 (en) 2017-11-23 2019-05-31 Inserm (Institut National De La Sante Et De La Recherche Medicale) A new marker for predicting the sensitivity to pi3k inhibitors
WO2019105734A1 (en) 2017-11-28 2019-06-06 Bayer Consumer Care Ag Combinations of copanlisib
WO2019105835A1 (en) 2017-11-29 2019-06-06 Bayer Consumer Care Ag Combinations of copanlisib and anetumab ravtansine
WO2019197269A1 (en) 2018-04-11 2019-10-17 Bayer Aktiengesellschaft Combinations of copanlisib with triazolone derivatives and their use in the treatment of cancer
WO2020020385A1 (zh) * 2018-07-27 2020-01-30 上海翰森生物医药科技有限公司 含三并环类衍生物抑制剂、其制备方法和应用
CN109053554B (zh) * 2018-08-01 2020-07-28 江苏八巨药业有限公司 一种使用催化剂合成3-乙酰吡啶的方法
EP3843743A1 (de) 2018-08-28 2021-07-07 Bayer AS Kombination von pi3k-inhibitoren und zielgerichteten thorium-konjugaten
WO2020078788A1 (en) 2018-10-16 2020-04-23 Bayer Aktiengesellschaft Combination of atr kinase inhibitors with 2,3-dihydroimidazo[1,2-c]quinazoline compounds
CA3118493A1 (en) 2018-11-05 2020-05-14 Iovance Biotherapeutics, Inc. Expansion of tils utilizing akt pathway inhibitors
EP3903828A4 (de) 2018-12-21 2022-10-05 Daiichi Sankyo Company, Limited Kombination aus antikörper-arzneimittel-konjugat und kinaseinhibitor
WO2020164997A1 (en) 2019-02-12 2020-08-20 Bayer Aktiengesellschaft Combination of pi3k-inhibitors
CN114621236B (zh) * 2022-04-25 2024-06-18 河南湾流生物科技有限公司 一种喹啉类饲料添加剂的制备方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3644354A (en) * 1968-09-16 1972-02-22 Sandoz Ag 5-substituted-2 3-dihydroimidazo(1 2-c)quinazolines
US4287341A (en) 1979-11-01 1981-09-01 Pfizer Inc. Alkoxy-substituted-6-chloro-quinazoline-2,4-diones
CN1033644C (zh) * 1993-01-02 1996-12-25 瑞安大药厂股份有限公司 3-取代甲基-2，3-二氢咪唑并[1，2-c]喹唑啉衍生物，其制备与用途
WO1996004923A1 (en) 1994-08-12 1996-02-22 Pro-Neuron, Inc. Methods for treating sepsis or inflammatory diseases with oxypurine nucleosides
WO1997027177A2 (en) * 1996-01-29 1997-07-31 The United States Of America, Represented By The Secretary, Department Of Health And Human Services Dihydropyridine-, pyridine-, benzopyran-4-one- and triazoloquinazoline derivatives, their preparation and their use as adenosine receptor antagonists
US5932584A (en) * 1997-05-06 1999-08-03 National Science Council Optically active 2,3-dihydroimidazo(1,2-C) quinazoline derivatives, the preparation and antihypertensive use thereof
ATE502941T1 (de) 2000-04-25 2011-04-15 Icos Corp Hemmer der menschlichen phosphatidyl-inositol-3- kinase delta
DE60144322D1 (de) * 2000-04-27 2011-05-12 Astellas Pharma Inc Kondensierte heteroarylderivate

Also Published As

Publication number Publication date
NO331457B1 (no) 2012-01-09
PE20050089A1 (es) 2005-04-20
KR101059652B1 (ko) 2011-08-25
KR20050067404A (ko) 2005-07-01
ECSP11005768A (es) 2011-03-31
IL166855A (en) 2014-05-28
DK2042504T3 (da) 2011-09-19
MA27483A1 (fr) 2005-08-01
ES2367141T3 (es) 2011-10-28
JP4790266B2 (ja) 2011-10-12
SI2042504T1 (sl) 2011-10-28
US20060128732A1 (en) 2006-06-15
TWI327570B (en) 2010-07-21
DE60324296D1 (de) 2008-12-04
UY28001A1 (es) 2004-04-30
TW200413379A (en) 2004-08-01
PT1549652E (pt) 2008-12-15
ES2312843T3 (es) 2009-03-01
CA2499134C (en) 2011-12-20
DK1549652T3 (da) 2009-02-23
HK1084393A1 (en) 2006-07-28
PL375935A1 (en) 2005-12-12
AR072458A2 (es) 2010-09-01
BR0314830A (pt) 2005-08-16
RU2005113165A (ru) 2005-10-10
EP1549652B1 (de) 2008-10-22
UA82205C2 (en) 2008-03-25
NO20052076L (no) 2005-04-27
AR041426A1 (es) 2005-05-18
RU2326881C9 (ru) 2009-04-10
WO2004029055A1 (en) 2004-04-08
BRPI0314830B8 (pt) 2021-05-25
EP2042504A1 (de) 2009-04-01
HRP20131159A2 (hr) 2014-05-23
ZA200503306B (en) 2006-07-26
CN1688582A (zh) 2005-10-26
PL226562B1 (pl) 2017-08-31
JP2006508063A (ja) 2006-03-09
US20090270388A1 (en) 2009-10-29
CY1112174T1 (el) 2015-12-09
AU2003293310A1 (en) 2004-04-19
CN100384846C (zh) 2008-04-30
RU2326881C2 (ru) 2008-06-20
US8129386B2 (en) 2012-03-06
MXPA05001808A (es) 2005-08-16
PT2042504E (pt) 2011-09-07
EP2042504B1 (de) 2011-06-01
CY1109790T1 (el) 2014-09-10
EP1549652A1 (de) 2005-07-06
SI1549652T1 (sl) 2009-04-30
ATE411996T1 (de) 2008-11-15
US7511041B2 (en) 2009-03-31
BRPI0314830B1 (pt) 2018-03-27
AU2003293310B2 (en) 2010-04-01
HRP20131159B1 (hr) 2019-11-01
HRP20050375A2 (en) 2006-05-31
ECSP055768A (es) 2005-08-11
NZ539062A (en) 2007-05-31
MY140756A (en) 2010-01-15
CA2499134A1 (en) 2004-04-08
HRP20050375B1 (hr) 2014-03-14

Similar Documents

Publication Publication Date Title
DE60324296D1 (de) Kondensierte azolpyrimidinderivate
ATE478870T1 (de) Spiroindolinpiperidinderivate
DK1556385T3 (da) Heterocyclocarboxamid-derivater
DE60330372D1 (de) Indol-3-schwefelderivate
ATE467631T1 (de) Chinuclidinamidderivate
IS7720A (is) Píperidín-N-oxíð-afleiður
ATE438644T1 (de) Chinazolinderivate
DK1474408T3 (da) N-Phenyl-2-pyrimidinaminderivater
NO20044046L (no) Substituerte hydroksyetylaminer
DE50311918D1 (de) Nockenwellenversteller
DE50302271D1 (de) Kondensor
ATE349458T1 (de) Etonogestrelester
ATE335729T1 (de) 3h-chinazoline -4-on derivaten
ATE423771T1 (de) Tetrahydrochinolinderivate
ATE496887T1 (de) Substituierte 5-aminomethyl-1h-pyrrol-2-carbons ureamide
ATA1572002A (de) Managementspleisskassette
ATE457299T1 (de) 4-hydroxymethyl-1-aryl-cyclohexylamin-derivativ
DE50306277D1 (de) 4-alkyl-/4-alkenyl-/4-alkinylmethyl/-1-arylcyclohexylamin-derivate
ATA4142004A (de) Trägerverbau
ATA19152002A (de) Hubkupplung
IS7906A (is) Afleiður própargýl-tríflúorómetoxý-amínó-benzóþíazóls
ATE396192T1 (de) N-sulfonylaminothiazole
DE50306228D1 (de) Substituierte benzdioxepine
AT5889U3 (de) Brennholzspleisser
ATA16872002A (de) Zwischenstück

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 2042504

Country of ref document: EP